Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FAK siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intraperitoneal, Parenteral
01
Overview
FAK siRNA is a small interfering RNA (siRNA) designed to specifically silence the expression of Focal Adhesion Kinase (FAK), a non-receptor tyrosine kinase encoded by the PTK2 gene. FAK is a key regulator of cell adhesion, migration, and survival, and its overexpression is associated with tumor progression and metastasis in various cancers. In research settings, FAK siRNA is used as a tool to investigate the functional role of FAK in signaling pathways, such as the FAK/Src axis. For instance, studies in endometrial cancer cell lines have demonstrated that knockdown of FAK using siRNA can abolish kisspeptin-induced phosphorylation of FAK and Src, leading to the inhibition of matrix metalloproteinase-2 (MMP-2) activation and a subsequent reduction in cell motility and invasiveness.
- Other names
- PTK2 siRNAPTK-2 siRNAPTK 2 siRNAfocal adhesion kinase siRNAHuman FAK siRNA
02
Targets
Focal adhesion kinase 1 (PTK2) mRNAPRR (Pattern recognition receptors)
Beyond the preview
Go deeper on FAK siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FAK siRNA.